KUALA LUMPUR, Nov 21 – IHH Healthcare has led a minority investment in Singapore-based genomic medicine company Lucence to provide cancer patients diagnostics and AI-driven analytics.
Lucence uses liquid biopsy, a blood-based technology that is less invasive than tissue biopsies, to aid researchers to discover a range of information about a tumour and aid in their treatment decisions, through a simple blood sample.
The treatment focuses on Asia-prevalent cancers such as lung, breast, colorectal, pancreatic, nasopharyngeal and liver cancers.
“Our investment in Lucence will provide IHH patients with better access to this advanced technology,” said Dr Kelvin Loh, Chief Executive Officer (Designate) of IHH, in a statement.
“IHH looks to drive greater synergies with Lucence and co-develop solutions for patients, as well as explore opportunities to sharpen our precision medicine capabilities with other like-minded partners across our 10-country network.”
Lucence CEO and founder Dr Min-Han Tan said: “Our research discoveries, such as the identification of the circulating tumour-endothelial cluster, can transform the liquid biopsy field, allowing better non-invasive cancer screening and profiling for patients.
“This partnership with IHH Healthcare will accelerate more groundbreaking research to achieve early cancer detection and effective cures, and expand access to this much-needed liquid biopsy technology to patients across Asia and the United States.”
The cooperation is part of IHH’s work with startups to deploy innovative and cutting-edge healthcare technology to enhance the patient experience, treatment and clinical outcomes across its network of 80 hospitals in 10 countries.